Biology:SLAMF7
From HandWiki
Revision as of 21:20, 13 August 2022 by imported>MainAI6 (add)
 Generic protein structure example |
SLAM family member 7 is a protein that in humans is encoded by the SLAMF7 gene.[1][2][3]
The surface antigen CD319 (SLAMF7) is a robust marker of normal plasma cells and malignant plasma cells in multiple myeloma. In contrast to CD138 (the traditional plasma cell marker), CD319/SLAMF7 is much more stable and allows robust isolation of malignant plasma cells from delayed or even cryopreserved samples.[4]
Elotuzumab is an antibody that targets this protein.
References
- ↑ "A novel immunoglobulin superfamily receptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion". The Biochemical Journal 361 (Pt 3): 431–6. Feb 2002. doi:10.1042/0264-6021:3610431. PMID 11802771.
- ↑ "Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily". Immunogenetics 52 (3–4): 302–7. Feb 2001. doi:10.1007/s002510000274. PMID 11220635.
- ↑ "Entrez Gene: SLAMF7 SLAM family member 7". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=57823.
- ↑ "Robust isolation of malignant plasma cells in multiple myeloma". Blood 123 (9): 1336–40. Feb 2014. doi:10.1182/blood-2013-09-529800. PMID 24385542.
Further reading
- "Regulation of NK cell activity by 2B4, NTB-A and CRACC". Frontiers in Bioscience 13 (13): 956–65. 2007. doi:10.2741/2735. PMID 17981603.
- "DNA cloning using in vitro site-specific recombination". Genome Research 10 (11): 1788–95. Nov 2000. doi:10.1101/gr.143000. PMID 11076863.
- "Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs". Genome Research 11 (3): 422–35. Mar 2001. doi:10.1101/gr.GR1547R. PMID 11230166.
- "Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family". Journal of Immunology 167 (10): 5517–21. Nov 2001. doi:10.4049/jimmunol.167.10.5517. PMID 11698418.
- "Mouse novel Ly9: a new member of the expanding CD150 (SLAM) family of leukocyte cell-surface receptors". Immunogenetics 54 (6): 394–402. Sep 2002. doi:10.1007/s00251-002-0483-3. PMID 12242590.
- "The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2)". The Journal of Biological Chemistry 278 (19): 17430–7. May 2003. doi:10.1074/jbc.M301569200. PMID 12621057.
- "Signal peptide prediction based on analysis of experimentally verified cleavage sites". Protein Science 13 (10): 2819–24. Oct 2004. doi:10.1110/ps.04682504. PMID 15340161.
- "Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs". European Journal of Immunology 34 (10): 2791–9. Oct 2004. doi:10.1002/eji.200424917. PMID 15368295.
- "From ORFeome to biology: a functional genomics pipeline". Genome Research 14 (10B): 2136–44. Oct 2004. doi:10.1101/gr.2576704. PMID 15489336.
- "The LIFEdb database in 2006". Nucleic Acids Research 34 (Database issue): D415-8. Jan 2006. doi:10.1093/nar/gkj139. PMID 16381901.
- "2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells". International Immunology 18 (2): 241–7. Feb 2006. doi:10.1093/intimm/dxh358. PMID 16410313.
- "CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes". Journal of Immunology 179 (7): 4672–8. Oct 2007. doi:10.4049/jimmunol.179.7.4672. PMID 17878365.
- "CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma". American Journal of Cancer Research 7 (8): 1637–41. Aug 2017. PMID 28861320.
 |
